Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • PET-CT for staging and or restaging in patients with suspected renal or bladder cancer

Title

Output Type

Speciality

Published

Title

PET-CT for staging and or restaging in patients with suspected renal or bladder cancer

Output Type

Advice Statement

Speciality

Cancer, Genitourinary system

Published

5 December 2017

Recommendation for NHSScotland

There was evidence from meta-analyses of small numbers of patients (n=535 and n=253, respectively) that FDG PET-CT is effective for detecting disease recurrence or metastases in patients with suspected renal or bladder cancer following indeterminate findings on conventional imaging. Evidence from a small number of observational studies suggests that FDG PET-CT findings influence treatment decisions in up to half of patients with suspected renal or bladder cancer following indeterminate conventional imaging results. No studies were identified that reported long-term oncological or quality of life outcomes resulting from changes in patient management.

Therefore it is uncertain what impact FDG PET-CT findings have on long-term patient outcomes. No evidence was identified which assessed the cost-effectiveness of FDG PET-CT in patients with urological cancers.

Therefore, no conclusions could be drawn about the cost-effectiveness of FDG PET-CT in this patient group.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

Is FDG PET-CT clinically and costeffective for staging and/or restaging in patients with suspected renal or bladder cancer following an abnormal result on contrast-enhanced CT or MRI?

Why is this important?

Conventional radiological imaging for suspected urological cancers includes ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy. 18F-fluorodeoxyglucose positron emission tomography - computed tomography (FDG PET-CT) is an additional imaging modality that could potentially be used for staging or restaging in patients with suspected renal or bladder cancer following indeterminate findings on conventional imaging.

Referred by

The Scottish PET-CT Working Group

Download icon
Download Advice
pdf (345 KB)
Download icon
Download Evidence Note
pdf (841 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?